MIG - Press Review

 

2016

Alternativer Text

Capital Heft Dezember -

Top 40 under 40

The economic journal “Capital” runs a cover story on Germany’s young elite featuring Andreas Kunze, CEO of MIG portfolio company Konux.
Alternativer Text

Süddeutsche Zeitung -

Funds for founders

Michael Motschmann, General Partner and member of the Executive Board at MIG AG, is quoted several times in an article by the Süddeutsche Zeitung on the funding options for start-up companies.
Alternativer Text

Handelsblatt -

German biotechnology: foreign companies want in

The Handelsblatt has published an article shedding some light on the sale of MIG portfolio company Ganymed to Japanese pharmaceutical company Astellas. MIG is named as the venture capitalist.
Alternativer Text

Handelsblatt -

Digital prize "The Spark" – More guts will do you good

Handelsblatt and McKinsey have awarded Konus and NaVvis, two portfolio companies of MIG Fonds, with the digital prize “The Spark” for innovations in industry 4.0.

Find out more

Alternativer Text

Euro am Sonntag -

We’re at the beginning of an era

Jürgen Eck, CEO of BRAIN AG, a MIG portfolio company, explains why he believes the trend for natural solutions in the chemical and consumer goods industry will keep on growing and growing.
Alternativer Text

Handelsblatt -

Efficient Energy - cool stuff

Handelsblatt presents Efficient Energy, a MIG portfolio company, and describes their new refrigeration technology as an innovative breakthrough. MIG Fonds are named as venture capitalists.

Find out more

Alternativer Text

F.A.S. -

Millions from California for the biotech pioneers from Mainz

Frankfurter Allgemeine Sonntagszeitung publishes an article about partnership between BioNTech, a MIG portfolio company, and the pharmaceutical company Genentech. Genentech has made an upfront payment of 310 million dollars to BioNTech.
Alternativer Text

Fierce Biotech -

Genentech lays $310M wager on BioNTech’s mRNA cancer vaccine platform

The trade journal FierceBiotech outlines the newest deal involving the payment of 310 million USD to MIG portfolio company BioNTech from Roche’s affiliated company Genentech.

Find out more

Alternativer Text

EP Vantage -

Biontech deal sees Roche bet on mRNA

The article by EP Vantage covers the latest partnership entered into by MIG portfolio company BioNTech aiming to advance developments of mRNA-based cancer vaccines. The pharmaceutical group Roche is also in on the latest deal.

Find out more

Alternativer Text

VC Magazin -

Interview with Michael Motschmann and Dr. Matthias Kromayer

The two MIG AG Executive Board members comment to recent successful exits, flotation of MIG portfolio company BRAIN and their next strategical moves with Venture Capital Magazin.
Alternativer Text

Harvard Business Manager -

Inspiration in instalments

For a case study conducted by Harvard Business Manager, Dr. Matthias Kromayer, member of the Executive Board at MIG AG, discusses three principles of strategic company management.
Alternativer Text

Frankfurter Allgemeine Sonntagszeitung -

The dream team of the biotech industry

Frankfurter Allgemeine Sonntagszeitung presents Özlem Türeci and Ugur Sahin, CEOs of Ganymed and BioNTech respectively. Both companies belong to the MIG portfolio.
Alternativer Text

Süddeutsche Zeitung -

Playing with your own money “kills your ego”

Profile of the MIG portfolio company Konux and its co-founder Andreas Kunze.

Find out more

Alternativer Text

Fierce Biotech -

Billionaire-backed Ganymed grabs ASCO spotlight

The renowned trade journal FierceBiotech reports on ASCO, the largest oncology congress in the world. MIG portfolio company Ganymed is one of the stars of the show with their new phase 2b trial.

Find out more

Alternativer Text

Wirtschaftswoche -

First universal cancer vaccine within reach

The article outlines MIG portfolio company BioNTech’s ground-breaking progress in the fight against cancer.

Find out more

Alternativer Text

FAZ -

Off through the museum with a ‘data hoover’

FAZ has published a detailed article discussing how the 3D trolley developed by NavVis, an MIG portfolio company, captures and maps interior spaces.

Find out more

Alternativer Text

Handelsblatt -

Start-up company Konux – the defect detector

Smart sensors and prominent investors: MIG portfolio company Konux wants to revolutionise the untended German industry by helping to eliminate faults before they even occur.

Find out more

Alternativer Text

Finanzwelt -

An addition to the MIG Fonds portfolio

Finanzwelt talks about MIG Fonds‘ acquisition of a 16.26 % share in Konux Inc in a series A round, making Konux the youngest company in MIG’s portfolio.

Find out more

Alternativer Text

Focus Online -

China stumps up billions for German entrepreneurs

Heinrich von Pierer describes the latest trend, whereby Chinese sovereign wealth funds are ending up in Germany as venture capitalist funds – a development which can even create opportunities for MIG.

Find out more

Alternativer Text

Handelsblatt -

Cancer vaccines

Handelsblatt presents Biontech as an inspiring start-up business in the biotech sector in a full-page profile, making several references to MIG Fonds as the participating VC investor.
Alternativer Text

Süddeutsche Zeitung -

One number, a worldwide connection

SZ features an article outlining the wide-reaching scope of the collaboration between Nfon, an MIG portfolio company, and German Telekom in developing cloud-based telephone systems.

Find out more

Alternativer Text

Manager Magazin -

A new Germany

NavVis, an MIG portfolio company, took pride of place as one of the hidden champions in an article listing over 50 successful digital business models.

Find out more

Alternativer Text

Handelsblatt -

Indoor satnavs

Handelsblatt has published an extensive profile on NavVis, citing MIG AG as a key VC investor who has been channeling money into the up-and-coming business since 2014.
Alternativer Text

Börsen-Zeitung -

Brain risks IPO despite the storm raging on the stock market

The response to being given the go-ahead for an IPO was obviously so good that the biotech firm Brain wants to follow through with its first steps onto the capital market despite the storm that’s currently raging.
Alternativer Text

Focus Online -

Technological company Brain goes public

Dr. Heinrich von Pierer has written an article explaining what consequences the IPO of Brain AG, an MIG Fonds portfolio company, will have for the German start-up business scene.

Find out more

Alternativer Text

DLD -

Jury awards top-class prize to NavVis

This year, the internationally renowned DLD prize “Digital Star” goes to NavVis, an MIG Fonds portfolio company. The start-up company from Munich won the main prize entitled “Innovation of the Year”.

Read more …

Alternativer Text

Börsen-Zeitung -

When Microorganisms solve problems

Börsen-Zeitung sheds some light on Brain AG’s business model, as well as their plans for the stock market. The article names MIG as an essential investor.